Trials / Completed
CompletedNCT03585296
A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis
A Phase 2 Safety Study of ATI-502 Topical Solution in Subjects With Moderate to Severe Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Aclaris Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, multicenter study designed to evaluate the safety and tolerability of ATI-502 Topical Solution in male and female subjects with moderate or severe atopic dermatitis (AD). Subjects will be required to apply ATI-502 study medication to their identified AD treatment areas. All subjects will be required to complete a safety follow up visit 4 weeks post last study medication application
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ATI-502 | Topical Solution |
Timeline
- Start date
- 2018-07-10
- Primary completion
- 2019-04-25
- Completion
- 2019-04-25
- First posted
- 2018-07-13
- Last updated
- 2020-02-17
- Results posted
- 2020-02-06
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03585296. Inclusion in this directory is not an endorsement.